Multicenter, Randomized, Controlled Phase III Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Compared to Control in Adult Patients Requiring Hospitalization for Medical Treatment of Moderate COVID-19 Infection
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PHARMA MAR, SA
- Phase: III
- Execution start: 11/01/2022
- End of execution: 30/05/2022
- PI: CARMEN HIDALGO TENORIO